@article{oai:repo.qst.go.jp:00046529,
 author = {Jin, Zhao-Hui and Sogawa, Chizuru and Furukawa, Takako and Saito, Yuriko and U, Winn Aung and Fujibayashi, Yasuhisa and Saga, Tsuneo and 金 朝暉 and 曽川 千鶴 and 古川 高子 and 齋藤 有里子 and Ｕ Ｗｉｎｎ Ａｕｎｇ and 藤林 康久 and 佐賀 恒夫},
 issue = {6},
 journal = {Molecular Imaging},
 month = {Dec},
 note = {AbstractAs cancer stem cells (CSCs) are postulated to play critical roles in cancer development, including metastasis and recurrence, CSC imaging would provide valuable information for cancer treatment and lead to CSC-targeted therapy. To assess the possibility of in vivo CSC targeting, we conducted basic studies on radioimmunotargeting of cancer cells positive for CD133, a CSC marker recognized in various cancers. Antibodies against CD133 were labeled with 125I, and their in vitro cell binding properties were tested. Using the same isotype IgG as a control, in vivo biodistribution of the labeled antibody retaining immunoreactivity was examined in mice bearing an HCT116 xenograft in which a population of the cancer cells expressed CD133. Intratumoral distribution of the labeled antibody was examined and compared to the CD133 expression pattern. The 125I-labeled anti-CD133 antibody showed a modest but significantly higher accumulation in the HCT116 xenograft compared to the control IgG. The intratumoral distribution of the labeled antibody mostly overlapped with the CD133 expression, whereas the control IgG was found in the area close to the necrotic tumor center. Our results indicate that noninvasive in vivo targeting of CSCs could be possible with radiolabeled antibodies against cell membrane markers.},
 pages = {445--50},
 title = {Basic Studies on Radioimmunotargeting of CD133-Positive HCT116 Cancer Stem Cells.},
 volume = {11},
 year = {2012}
}